TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06588478: A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Re

Sponsor: Loxo Oncology, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 249 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06588478 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06588478 Rescue Dossier →